Swinkels Helena M., Koury Ron, Warrington Steven J.
University of British Columbia
Orange Park Medical Center
Rabies has been a much-feared disease affecting humans and animals since antiquity due to its near-uniform fatality once symptoms appear. Following an incubation period ranging from a few days to a few years, rabies presents with a vague, febrile illness, frequently with pain and paresthesias at the wound site. Within 2 weeks, the neurological phase typically progresses into encephalitic or paralytic rabies, followed by coma. Death typically occurs within 2 to 3 days of coma onset. Once symptoms begin, treatment typically focuses on minimizing the patient's pain and suffering. In resource-poor countries, many individuals die at home. Rabies (RABV) and other similar viruses are zoonotic, neurotropic viruses belonging to the family Rhabdoviridae, genus . These viruses cause indistinguishable clinical illnesses. Rabies is distributed worldwide, infecting various mammals, including dogs, cats, bats, livestock, and wildlife. The RABV is transmitted through the saliva of infected animals, contaminating bites, open skin, or mucous membrane, and, in rare cases, through organ transplantation. Dog bites account for 99% of rabies cases, making dogs the primary reservoir worldwide. Human rabies is rare in resource-rich countries but remains a significant public health concern in resource-limited regions, causing tens of thousands of deaths annually. The burden is highest in Asia and Africa, primarily affecting children in areas without large-scale preventive measures. All suspected and confirmed human and animal rabies cases must be reported to the appropriate hospital infection prevention and control programs, local public health authorities, or animal health authorities. Clinicians often overlook the diagnosis of rabies at the initial presentation. Preventing rabies is crucial, as treatment options after symptoms appear are mostly limited to palliative care. Following exposure, rabies postexposure prophylaxis (PEP) should be administered urgently, especially in deep or multiple bites in areas with dense nerve endings, such as the hands or regions close to the central nervous system (CNS), including the head and neck. PEP includes thorough wound cleansing, the administration of multiple cell culture-derived rabies vaccines, and human rabies immunoglobulin (HRIg) if the patient has not received prior rabies vaccination. Preexposure prophylaxis (PrEP) is available for individuals likely to be exposed to the RABV, such as veterinarians and long-term travelers or residents in endemic countries. Clinicians must be familiar with local guidelines to determine appropriate PEP, as animal carriers, the prevalence of rabies, and the availability of vaccines and HRIg vary by region. In the United States, the Advisory Committee on Immunization Practices (ACIP) developed national human rabies prevention guidelines with support from the Centers for Disease Control (CDC) in 2008, updating them in 2010 to reduce the number of vaccines required for PEP. Local or state public health authorities develop guidelines specific to the region. The World Health Organization (WHO) revised its 2010 rabies vaccine position paper in 2018 to improve programmatic feasibility, simplify vaccination schedules, and improve cost-effectiveness. The opportunity to provide appropriate postexposure rabies prophylaxis may be missed due to patient, clinician, or structural factors. Patients may be unaware that a specific exposure carries a risk or may not realize they were bitten, especially in cases of bat bites. Clinicians may be unaware of the local rabies epidemiology where the bite occurred or appropriate pre- or postexposure treatment. On the systemic level, a lack of PEP availability due to geographic factors or the prohibitively high cost of PEP results in lost opportunities for treatment. Mass dog vaccination is the most cost-effective strategy for preventing dog-mediated human rabies worldwide. In its 2017 global strategic plan, the United Against Rabies coalition, in collaboration with the WHO and other global animal and human health organizations, aims to eliminate human rabies by 2030. This activity reviews PrEP and PEP, the diagnosis and treatment of clinical rabies, public health management of rabies cases, and rabies control. Please see StatPearls' companion resource, "Animal Bites," for further information.
自古以来,狂犬病就是一种令人闻风丧胆的疾病,它会影响人类和动物,因为一旦出现症状,其致死率几乎是百分之百。经过几天到几年不等的潜伏期后,狂犬病最初表现为一种模糊的发热性疾病,伤口部位常常伴有疼痛和感觉异常。在两周内,神经期通常会发展为脑炎型或麻痹型狂犬病,随后进入昏迷状态。死亡通常发生在昏迷开始后的2至3天内。一旦出现症状,治疗通常侧重于减轻患者的疼痛和痛苦。在资源匮乏的国家,许多患者在家中死亡。狂犬病病毒(RABV)和其他类似病毒是属于弹状病毒科的人畜共患嗜神经病毒。这些病毒会引发难以区分的临床疾病。狂犬病在全球范围内都有分布,感染各种哺乳动物,包括狗、猫、蝙蝠、家畜和野生动物。狂犬病病毒通过受感染动物的唾液传播,污染咬伤处、开放性皮肤或黏膜,在极少数情况下,也可通过器官移植传播。99%的狂犬病病例是由狗咬伤所致,这使得狗成为全球主要的病毒宿主。在资源丰富的国家,人类狂犬病病例较为罕见,但在资源有限的地区,它仍然是一个重大的公共卫生问题,每年导致数万人死亡。亚洲和非洲的负担最为沉重,主要影响那些没有大规模预防措施地区的儿童。所有疑似和确诊的人类及动物狂犬病病例都必须报告给相应医院的感染预防与控制项目、当地公共卫生当局或动物卫生当局。临床医生在初次接诊时常常会忽略狂犬病的诊断。预防狂犬病至关重要,因为出现症状后的治疗选择大多仅限于姑息治疗。暴露后,应立即进行狂犬病暴露后预防(PEP),尤其是在手部或靠近中枢神经系统(CNS)的区域(如头部和颈部)发生的深度或多处咬伤,这些部位神经末梢密集。PEP包括彻底清洗伤口、接种多剂细胞培养狂犬病疫苗,如果患者之前未接种过狂犬病疫苗,还需注射人狂犬病免疫球蛋白(HRIg)。对于可能接触狂犬病病毒的个体,如兽医以及流行国家的长期旅行者或居民,可进行暴露前预防(PrEP)。临床医生必须熟悉当地的指导方针,以确定合适的PEP,因为动物宿主、狂犬病的流行情况以及疫苗和HRIg的可获得性因地区而异。在美国,免疫实践咨询委员会(ACIP)在疾病控制中心(CDC)的支持下,于2008年制定了国家人类狂犬病预防指南,并于2010年进行了更新,以减少PEP所需的疫苗数量。地方或州公共卫生当局制定适用于该地区的具体指南。世界卫生组织(WHO)于2018年修订了其2010年的狂犬病疫苗立场文件,以提高项目的可行性、简化疫苗接种程序并提高成本效益。由于患者、临床医生或结构因素,可能会错过提供适当的暴露后狂犬病预防的机会。患者可能不知道特定的暴露存在风险,或者可能没有意识到自己被咬伤,尤其是在被蝙蝠咬伤的情况下。临床医生可能不了解咬伤发生地的当地狂犬病流行病学情况或适当的暴露前或暴露后治疗方法。在系统层面,由于地理因素导致PEP无法获得,或者PEP成本过高,从而错失治疗机会。大规模犬类疫苗接种是全球预防犬传人狂犬病最具成本效益的策略。在其2017年全球战略计划中,狂犬病防治联盟与世界卫生组织以及其他全球动物和人类健康组织合作,旨在到2030年消除人类狂犬病。本活动回顾了暴露前预防和暴露后预防、临床狂犬病的诊断和治疗、狂犬病病例的公共卫生管理以及狂犬病控制。有关更多信息,请参阅StatPearls的配套资源“动物咬伤”。